$0.00
0.00 (-11.36%)
Open$0.00
Previous Close$0.00
Day High$0.00
Day Low$0.00
52W High$2.79
52W Low—
Volume—
Avg Volume433.9K
Market Cap316.6K
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+942,976.9% upside
Current
$0.00
$0.00
Target
$36.78
$36.78
$22.85
$36.78 avg
$42.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.46M | 14.50M | 15.97M |
| Net Income | 527.9K | 404.7K | 468.6K |
| Profit Margin | 3.2% | 2.8% | 2.9% |
| EBITDA | 822.7K | 875.9K | 889.3K |
| Free Cash Flow | 305.6K | 207.6K | 283.2K |
| Rev Growth | +9.2% | +19.8% | +5.1% |
| Debt/Equity | 1.41 | 1.41 | 1.44 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |